NEW YORK (GenomeWeb News) — A research team at the University of Colorado, Boulder has received $14.6 million from the Defense Advanced Research Projects Agency to develop a system that will use microfluidics and mass spectrometry to determine how drugs and biological or chemical agents affect human cells.

The team at UC-Boulder's BioFrontiers Institute will use the cooperative agreement award to fund the Subcellular Pan-Omics for Advanced Rapid Threat Assessment (SPARTA) project, UC-Boulder said Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.